Join experts from Enago Life Sciences to learn best practices for navigating the balance between efficiency and authority in expedited publishing.
As Med Ed teams adopt new tech, it’s key to know how physicians prefer learning. This article shares 2025 MAPS tips with simple “do THIS, not THAT” strategies.
Medical Affairs gathers insights from both internal and external sources, disseminating them cross-functionally to support a range of applications, including evidence generation planning, content development, HCP engagement, customer targeting, and strategy development. This article highlights key learnings from the ‘Omnichannel Insights – Driving Engagement Strategy’ forum.
This article summarizes insights from a 2025 MAPS Roundtable where Medical Affairs leaders discussed emerging trends in digital engagement, focusing on the rise of Digital Opinion Leaders (DOLs) and strategies for Healthcare Professional (HCP) influence mapping. The conversation highlighted how innovative approaches are reshaping disease awareness and stakeholder relationships.
Is Bluesky the new Twitter (X) for academic research conversations? Learn how Medical Affairs teams can maximize the opportunity of this new platform.
Pharma launch plans often overlook a critical driver of success: a formal insights strategy.
In what is certainly a new high or a new low for this podcast, we explore how to calculate the “Kardashian Index” of your KOLs and scientific leaders.
Johnson & Johnson’s Medical Affairs team is transforming strategy with data-driven insights, moving beyond traditional approaches to identify key opinion leaders, improve advisory board diversity, and enhance patient journey mapping. With H1’s analytics, they are shifting from quantity to quality in engagements, advancing health equity, and leveraging AI for smarter decision-making.
In this On-Demand webinar, you will focus on key learnings from the pilot and explore expansion in usage of this emerging technology.
The objective of this article is to discuss the paradigm shift in how companies plan for and deliver on the “long tail” of a drug’s impact even after Loss of Exclusivity (LoE) – a process known as lifecycle management (LCM).